• Publications
  • Influence
Serum levels of the progesterone induced blocking factor do not precipitously rise in women with gynecologic cancer in contrast to women exposed to progesterone.
PURPOSE To determine if an immunomodulatory protein (progesterone induced blocking factor [PIBF]) that is progesterone induced and found in higher concentration during pregnancy is similarly foundExpand
Lymphocyte immunotherapy can improve pregnancy outcome following embryo transfer (ET) in patients failing to conceive after two previous ET.
PURPOSE To determine if lymphocyte immunotherapy (LIT) can improve the outcome after embryo transfer (ET) in women failing to have a live delivery after at least two previous attempts. METHODSExpand
The progesterone receptor antagonist mifepristone does not lower serum progesterone induced blocking factor (PIBF) in the presence of progesterone.
PURPOSE To determine if mifepristone can lower serum levels of a progesterone (P) induced immunomodulatory protein believed to be needed for the fetus to escape immune surveillance. MATERIALS ANDExpand
Abstract 1282: Comparison of serum progesterone levels of the immunomodulatory protein, the progesterone induced blocking factor, in people with BRCA-2 mutations associated with and not associated
The BRCA genes normally provide proteins important in degradating the progesterone (P) receptor. BRCA1 and 2 mutations may make mutated protein, leading to prolongation of P receptor activity whichExpand
Matched control study of efficacy of lymphocyte immunotherapy in donor oocyte recipients to support or refute the concept of need for histocompatibility antigen sharing of the couple for benefits.
PURPOSE To determine if lymphocyte immunotherapy (LIT) improves outcome in recalcitrant donor oocyte recipients. If LIT was found to be similarly effective in this group, the theory of sharedExpand